Discovery › watchlist
Watchlist verify holds
Resolving the six large/unexplained moves flagged in the 2026-07-14 watchlist scan. One is a material data error (CRWD split).
🔴 CRWD — CrowdStrike — DATA ERROR: 4-for-1 stock split (Jul 2, 2026)
A portfolio-specific passage was removed from the public build.
🟢 SANM — Sanmina — obsolete "exit" note; it's an AI-infra winner
The "EXIT — $13 dead capital, tariff headwinds" note is void. Q2 2026: rev +102% YoY to $4.01B (ZT Systems + AI/cloud infra), non-GAAP EPS +125% to $3.16 (beat by $0.76). Raised FY2026 rev to $13.7–14.3B; FY2027 target >$16B / ~$11 EPS; $600M buyback. AI/cloud = 62% of revenue. Up ~173% in a year; now ~$206 (+104% vs cost). Trades ~18–20x FY27 EPS. - Action: HOLD / let run (do NOT exit). Consider trimming into strength given the 20x-forward re-rating (BofA Neutral $280, Argus Buy $200). Thesis transformed from commodity EMS → AI-data-center manufacturing.
🟢 PANW — Palo Alto Networks — real rally, near ATH
No recent split distortion on the move; genuine run to near its all-time high (~$357, Jul 6, 2026) on AI-cybersecurity momentum. ~$350 now = +141% vs cost — a legitimate winner above trim ($230+). - Action: TRIM candidate. Platform-consolidation thesis intact; take some profit into strength.
🟡 DOCN — DigitalOcean — AI re-rating; old "exit" note stale
Doubled (+100%) on a genuine pivot: Q1 2026 AI-related ARR +221%, launched AI-Native Cloud + Inference Engine (Deploy 2026), raised FY2027 growth outlook to ~50%, promoted S&P SmallCap 600 → MidCap 400, analyst upgrades (Goldman PT $179, Canaccord $120). - The old "87% D/A, weak, consider exit" concern is superseded by the AI story — but the debt (87% D/A) and an $810M equity raise (dilution) are the real watch-items. - Action: HOLD / let run, monitor leverage & dilution. No longer an exit candidate.
🟡 ORCL — Oracle — the watchlist note was wrong; risk bigger, not gone
The row said "OpenAI walking away from expanding Stargate." The opposite happened: in July, OpenAI + Oracle + SoftBank expanded Stargate by +4.5 GW, part of a >$300B commitment; OCI rev +68% YoY to $4.1B; RPO $523B (+438%). - So the concentration risk is larger, not resolved — Oracle is now more dependent on OpenAI/Stargate, funded by >$100B debt and deeply negative FCF (down ~50% from highs; class actions piling up). - At $129.16 (below the $140–150 buy zone), ~13x fwd for 27%+ guided growth. Value case exists but it's a high-capex, single-customer-concentration, negative-FCF bet. - Action: correct the note. Stage carefully / cap size — heavy AI-capex overlap with AMD/ANET/AVGO already in book. Thesis break: OCI growth <40% 2 consec Q, dilutive raise, or OpenAI restructures.
🟡 ACN — Accenture — softening, but thesis-break lines not quite hit
Q3 FY2026 (Jun 18): rev $18.72B (+6% USD), EPS $3.80 (+9%) — a beat, BUT FY2026 guide trimmed to 3–4% LC and bookings $19.3B, −2–3%, book-to-bill 1.0. The stated thesis-break triggers ("bookings <$15B" / "guide <3%") are not technically hit (bookings still $19.3B; guide 3–4%, at the edge). But the AI-services-repricing deceleration is now confirmed in the numbers, and price broke the $145 stop ($134.90). - FCF strong; 104 mega-deals ($100M+) YTD, +13%. 11x fwd, 3.9% yield. - Action: HOLD; do not average down aggressively. Treat like CTSH (value-vs-value-trap in AI-disrupted IT services) — wait for bookings to re-accelerate. Correlates with held CTSH/EPAM; manage combined exposure. Consider conviction trim to [6.5].
A portfolio-specific passage was removed from the public build.
Sources: CRWD 4:1 split, SANM Q2, PANW ATH, DOCN AI, ORCL/Stargate, ACN Q3. Public.com quotes.